Abraxane monotherapy is indicated for the treatment of metastatic breast cancer The recommended dose of Abraxane in combination with gemcitabine is Attachment 1: Product information for AusPAR Abraxane paclitaxel (nab) Abraxis PM Date of Finalisation 17 June This Product. Learn more about ABRAXANE®, including dosing, efficacy, and safety information. This site is intended for US healthcare professionals only.
|Published (Last):||24 August 2007|
|PDF File Size:||12.72 Mb|
|ePub File Size:||7.5 Mb|
|Price:||Free* [*Free Regsitration Required]|
Current line of chemotherapy for advanced disease [median range ]. New guidelines to evaluate the response to treatment in solid tumors. Median duration of therapy was 5. Every 3 abraxanr q3w. Peripheral neuropathy induced by paclitaxel: Women receiving nab-paclitaxel had a median overall survival of Patients Between June and December43 patients with mbc received treatment with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre, ahraxane 42 patients were evaluable for clinical response.
Steroid premedication was not required before administration of therapy. Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel [abstract ] J Clin Oncol. Although the median overall survival for all women treated with nab-paclitaxel was Footnotes a Abraxis BioScience, data on file. Improved effectiveness of nanoparticle albumin-bound nab paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of her 2 and sparc status.
In addition, it has been suggested that the Cremophor solvent used in the preparation of paclitaxel may have a direct negative effect on the antitumour properties of that drug Author information Copyright and License information Disclaimer. J Clin Oncol ; Significantly longer progression-free survival with nab-paclitaxel compared with abraxzne as first-line therapy for metastatic breast cancer.
Nab-paclitaxel was administered weekly qw: Radiologic and clinical assessments were performed at the discretion of the treating physician.
In this group, mean age was 57 years range: Clinical benefit was defined as partial or complete response or stable disease by clinical or radiologic evaluation, or both at 6 months or more. These synthetic solvents are associated with the development of acute hypersensitivity reactions and peripheral neuropathy 4 and so require premedication with corticosteroids, antihistamines, and H 2 a ntagonists Taxotere P I: Table i summarizes patient demographics and abraxae characteristics.
Demographic and clinical data are summarized descriptively as means, medians, or proportions. Clinical benefit was based on clinical and radiologic assessments for example, computed tomography imaging of patients, which were requested by the treating physicians at variable points in time.
Demographic and treatment characteristics of patients with metastatic breast cancer receiving nab-paclitaxel. The optimal dose and schedule of nab-paclitaxel has yet to be clearly defined.
The remaining authors have no financial conflicts of interest to disclose. Those results differ from the findings reported from the phase pu trial by Gradishar et al. Regardless of dosing schedule, women experiencing clinical benefit lived significantly longer than those not experiencing a benefit Clinical outcomes data in patients with metastatic breast cancer receiving nab-paclitaxel on a weekly qw and everyweeks q3w schedule.
ABRAXANE – Prescribing Information
xbraxane In our experience, most women with mbc treated with single-agent nab-paclitaxel some having received up to 6 prior lines of chemotherapy experienced some degree of clinical benefit with an acceptable level of toxicity.
Survival curves for patients who achieved and did not achieve clinical benefit from nab-paclitaxel. Dose reductions, mainly because of toxicity, were more common with q3w administration Patients who had received taxane docetaxel or paclitaxel chemotherapy adjuvant or metastatic setting before receiving nab-paclitaxel were also included.
Clinical benefit was evaluable in 42 patients. Survival curves were generated using the Kaplan—Meier method and were compared using the log-rank test.
ABRAXANE | Full Prescribing Information
National Center for Biotechnology InformationU. Eligible patients include those with acute infusion reactions with paclitaxel or docetaxel considered by treating physicians to be a result of the vehicle for the taxanes Cremophor and polysorbate 80severe toxicity from previous administration of other taxanes, or severe toxicity that might be attributable to premedications for example, steroids used for the administration of the taxane.
Those observations suggest that nab-paclitaxel may provide long-term disease control in the difficult-to-treat taxane-refractory mbc population. This analysis includes mbc patients treated with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre between June and December Phase iii trial of nanoparticle albumin-bound paclitaxel compared pii polyethylated castor oil—based paclitaxel in women with breast cancer. Of 43 women mean age: J Natl Cancer Inst.
Treatment was initially given in a qw schedule and switched to a q3w schedule in 1 patient 2. Nab-paclitaxel is a solvent-free, taxane-based chemotherapy approved for the abraxne of metastatic breast cancer mbc.
Patients who received coverage for nab-paclitaxel through the Ontario New Drug Funding Program or third-party funding private insurance were included. Nab-paclitaxel abraxxane was given to 20 patients Eligible patients for this study included all women with mbc who were treated with single-agent nab-paclitaxel at the Ottawa Hospital Cancer Centre.
In the Cox proportional hazards analysis, achievement of clinical benefit hr: Open in a separate window.
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.